Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 137.64
-10.63 (-7.17%)
At close: Oct 29, 2025
Neurocrine Biosciences Market Cap
Neurocrine Biosciences has a market cap or net worth of 10.47 billion as of October 31, 2025. Its market cap has increased by 15.68% in one year.
Market Cap
10.47B
Enterprise Value
9.99B
Revenue
2.00B
Ranking
n/a
PE Ratio
32.88
Stock Price
137.64
Market Cap Chart
Since May 23, 1996, Neurocrine Biosciences's market cap has increased from 136.97M to 10.47B, an increase of 7,543.87%. That is a compound annual growth rate of 15.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 30, 2025 | 10.47B | -5.16% |
| Dec 31, 2024 | 11.04B | 8.62% |
| Dec 29, 2023 | 10.16B | 6.65% |
| Dec 30, 2022 | 9.53B | 59.70% |
| Dec 31, 2021 | 5.97B | -9.03% |
| Dec 31, 2020 | 6.56B | -12.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 194.55B |
| GSK plc | 71.65B |
| Haleon | 31.24B |
| Smith & Nephew | 11.59B |
| ConvaTec Group | 4.84B |
| Hikma Pharmaceuticals | 4.04B |
| HUTCHMED (China) | 1.88B |
| Genus | 1.66B |